Teprotumumab is a promising new immunomodulatory therapy for thyroid eye disease. One unique adverse effect observed in clinical trials was hearing impairment; however, all adverse auditory effects in prior clinical trials resolved spontaneously after completion of teprotumumab therapy. The authors present a case of a patient on teprotumumab for thyroid eye disease who experienced sustained hearing loss secondary to shooting a rifle without ear protection. In this case, it is suspected the teprotumumab infusions resulted in increased susceptibility of the inner ear hair cells to noise-induced trauma secondary to IGF-IR inhibition. Specific ear protection protocols may need to be implemented in the future for patients on teprotumumab therapy to prevent sustained hearing loss, especially for susceptible patient populations.

中文翻译：

---

步枪爆炸加剧了接受 Teprotumumab 治疗甲状腺眼病的患者的听力损失。

Teprotumumab 是一种有前途的新型免疫调节疗法，用于治疗甲状腺眼病。临床试验中观察到的一种独特的不良反应是听力障碍。然而，先前临床试验中的所有不良听觉效应在替普罗妥尤单抗治疗完成后均自行缓解。作者介绍了一名因甲状腺眼病而服用 teprotumumab 的患者的病例，该患者因在没有耳朵保护的情况下射击步枪而出现持续性听力损失。在这种情况下，怀疑 teprotumumab 输注导致内耳毛细胞对继发于 IGF-IR 抑制的噪音诱发创伤的敏感性增加。未来可能需要对接受 teprotumumab 治疗的患者实施特定的耳朵保护方案，以防止持续性听力损失，特别是对于易感患者群体。